AI Article Synopsis
- The Roche COBAS AmpliPrep/COBAS TaqMan HCV Test (CAP/CTM) demonstrated a limit of detection at 9.5 IU/mL and showed strong reproducibility and linearity across different HCV genotypes.
- The CAP/CTM assay yielded higher HCV RNA measurements on average compared to the Roche Analyte Specific Reagent (ASR) and performed significantly better for genotype 3 samples compared to genotypes 1 and 2.
- Inhibition from common substances was minimal, and the CAP/CTM's overall performance supports its use in guiding treatment with direct acting antivirals like boceprevir and telaprevir.
Article Abstract
The performance of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test (CAP/CTM) was evaluated. The limit of detection was 9.5 IU/mL using the 3rd International Standard. Serial dilutions of each genotype demonstrated good reproducibility and linearity. Correlation with samples previously tested with the Roche Analyte Specific Reagent (ASR) was very good, with the CAP/CTM assay measuring 0.24 log IU/mL higher on average than ASR. Genotype inclusivity evaluated in the CAP/CTM, ASR, and Siemens Versant HCV RNA 3.0 Assay (bDNA) assay using a commercially available panel showed higher measurements than ASR or bDNA. The differences in observed CAP/CTM and ASR results for genotype 3 patient samples were significantly different (P < 0.05) from those for both genotype 1 and 2 samples. Common inhibitory substances had no more than a 0.25 log IU/mL affect. Overall, the automated CAP/CTM assay exhibits excellent sensitivity, reproducibility, and dynamic range. Its performance is compatible with its use in guiding therapy using direct acting antivirals such as boceprevir and telaprevir.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2013.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimating the economic consequences of leveraging the novel cobas® HIV-1/HIV-2 Qualitative NAT Test in routine HIV testing.
Clin Infect Dis
January 2025
IQVIA Inc., Falls Church, VA.
Article Synopsis
- The study compared the costs of the current CDC 3-step HIV testing algorithm with a new single-test alternative (cobas) for efficiency in diagnosing HIV.
- A decision-tree model estimated costs and testing needs for 1 million people, revealing significant reductions in total tests and retests required when using the alternative method.
- Findings indicate that the new algorithm could simplify HIV testing processes, cut overall testing numbers, and keep healthcare costs stable, thereby improving patient outcomes.
Comparability of the LDH measurement and analysis based on external quality assessment.
Clin Chim Acta
January 2025
Department of Clinical Laboratory, Beijing Chaoyang Hospital, The Third Clinical Medical College of Capital Medical University, Beijing Center for Clinical Laboratories, No. 8 Gongti South Road, Chaoyang District, Beijing 100020, PR China. Electronic address:
Background: Lactate dehydrogenase (LDH) is a critical enzyme widely used in clinical diagnostics. However, variations in measurement systems can lead to inconsistent results, potentially impacting clinical decision-making. This study aimed to evaluate the comparability of lactate dehydrogenase measurements by comparing routine methods with the IFCC reference method, and to analyze the standardization status of LDH testing through external quality assessment (EQA).
View Article and Find Full Text PDFBackground: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.
Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.
Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival.
Glucometer versus analyzer: comparable results with negligible clinical risk.
Scand J Clin Lab Invest
January 2025
Department of Medical Biochemistry, Health Science University, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
This study assessed the reliability of Roche Accu-Chek Inform II glucometers in a real-world setting. A retrospective analysis was conducted on 6,695 paired results. Capillary samples were tested using Roche Accu-Chek Inform II glucometers, while venous samples were analyzed using Roche Cobas c503/702 analyzers.
View Article and Find Full Text PDFComparison of Liquid-Based Cytology EASYPREP and SurePath for Detection of High-Risk HPV Genotypes.
Ann Clin Lab Sci
November 2024
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Objective: Molecular testing for high-risk human papillomavirus (hrHPV) genotypes is important for cervical cancer screening. In this study, we compared the HPV detection rates using real-time PCR in cervical samples collected using two different liquid-based cytology (LBC) kits.
Methods: Cervical swab specimens were prospectively collected using the SurePath and EASYPREP collection kits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!